Biodegradable Cisplatin Polymer in Limb-Sparing Surgery for Canine Osteosarcoma
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: The rate of local recurrence of osteosarcoma after limb-sparing surgery in dogs and humans has been reported up to 28%. The primary purpose of this study was to determine whether a biodegradable cisplatin-containing implant (OPLA-Pt), inserted into the limb-sparing surgery site at the time of surgery, would decrease the rate of local recurrence. Secondary aims included evaluation of systemic toxicity associated with the release of cisplatin from the implant and identification of prognostic factors associated with limb-sparing surgery for osteosarcoma in dogs.
Methods: Eighty dogs with spontaneously occurring osteosarcoma were treated with limb-sparing surgery. They were randomized to receive the biodegradable implant either without cisplatin (control group) or with cisplatin (OPLA-Pt group) and were targeted to receive four doses of an adjuvant cisplatin chemotherapy protocol.
Results: Although this was not statistically significant (P = .071), dogs in the OPLA-Pt group were 53.5% less likely to develop local recurrence than dogs in the control group. There were no significant differences in systemic toxicity between treatment arms. Incomplete surgical resection, absence of infection, and fewer than four doses of adjuvant chemotherapy had a significant correlation with local recurrence and survival according to univariate analyses, although only incomplete surgical resection remained significant for local recurrence after multivariate analysis.
Conclusions: Local tumor recurrence may be decreased after limb-sparing surgery by use of biodegradable implants impregnated with chemotherapeutic agents.
- Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system Withrow SJ, MacEwen EG Eds. Small Animal Clinical Oncology. Philadelphia: WB Saunders, 2001: 378–417.
- LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734–44.
- Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991;270:159–68.
- Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996;26:135–43.
- Kuntz CA, Asselin TL, Dernell WS, et al. Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet Surg 1998;27:417–22.
- Morello E, Buracco P, Martano M, et al. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 2001;42:61–6. CrossRef
- Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994;76:649–56.
- Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 1996;324:86–97.
- Sluga M, Windhager R, Lang S, et al. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop 1999;358:120–7.
- Renard AJ, Veth RP, Schreuder HW, et al. Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of the bone. J Surg Oncol 2000;73:198–205.
- Malawer MM, Link MP, Donaldson SS. Sarcomas of bone DeVita VT, Hellman S, Rosenberg SA Eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001: 1891–908.
- DiCaprio MR, Friedlaender GE. Malignant bone tumors: limb sparing versus amputation. J Am Acad Orthop Surg 2003;11:25–37.
- Nell MD, Shah N, Daw N, et al. 2002 Survival after local recurrence of osteosarcoma: the St. Jude Children’s Research Hospital experience, 1970–2000 Musculoskeletal Tum Soc Proc
- Theon AP, Madewell BR, Moore AS, Stephens C, Krag DN. Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumors. Int J Hyperthermia 1991;7:881–92.
- Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy experience in six dogs. J Vet Intern Med 1991;5:227–31.
- Straw RC, Withrow SJ, Douple EB, et al. Effects of cis-diamminedichloroplatinum II released from D, L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res 1994;12:871–7.
- Kitchell RB, Brown DM, Luck EE, et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 1994;204:229–36.
- Kitchell BK, Orenberg EK, Brown DM, et al. Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma. Eur J Cancer 1995;31:2093–8.
- Dernell WS, Withrow SJ, Straw RC, et al. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997;17:4499–506.
- Morello E, Dernell WS, Kuntz CA, et al. Evaluation of cisplatin in combination with a biologic response modifier in a murine mammary carcinoma model. Cancer Invest 2002;20:480–9.
- Kanno S, Hyodo M, Suzuli K, et al. Effect of DNA-damaging agents on DNA replication and cell-cycle progression of cultured mouse mammary carcinoma cells. Jpn J Cancer Res 1985;76:289–96.
- Sevin B, Pollack A, Averate HE, et al. In vivo cell kinetic effects of cis-platinum on human cancer xenografts measured by dual parameter flow cytometry. Cytometry 1987;8:153–62.
- Ehrhart N, Dernell WS, Ehrhart EJ, et al. Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice. Am J Vet Res 1999;60:1347–51.
- Mauldin GN, Matus RE, Withrow SJ, Patnaik K. Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177–80.
- Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507–11.
- Kraegel SA, Madewell BR, Simonson E, Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986–1989). J Am Vet Med Assoc 1991;199:1057–9.
- Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991;5:205–10.
- Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). J Am Vet Med Assoc 1992;200:2005–8.
- Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). J Am Vet Med Assoc 1992;200:531–3.
- Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Musculoskeletal Res 1995;4:105–10.
- Chun R, Kurzman ID, Cuoto CG, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 2000;14:495–8.
- Knapp DW, Richardson RC, Bonney PL, Hahn K. Cisplatin therapy in 41 dogs with malignant tumors. J Vet Intern Med 1988;2:41–6.
- Hardie EM, Page RL, Williams PL, Fischer WD. Effect of time of cisplatin administration on toxicity and pharmacokinetics in dogs. Am J Vet Res 1991;52:1821–5.
- Ogilvie GK, Straw RC, Powers BE, et al. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987–1989). J Am Vet Med Assoc 1991;199:613–6.
- Ogilvie GK, Fettman MJ, Jameson VJ, et al. Evaluation of one-hour saline diuresis protocol for administration of cisplatin to dogs. Am J Vet Res 1992;53:1666–9.
- Ogilvie GK, Straw RC, Jameson VJ, et al. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms. J Am Vet Med Assoc 1993;202:1845–8.
- Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
- Dernell WS, Withrow SJ, Straw RC, et al. Clinical response to antibiotic-impregnated polymethyl methacrylate bead implantation of dogs with severe osteomyelitis. Vet Comp Orthop Traumatol 1998;11:94–9.
- Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555–60.
- Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76–81. CrossRef
- Liptak JM, Dernell WS, Lascelles BDX, et al. 2001 Survival analysis of dogs with appendicular osteosarcoma treated with limb sparing surgery and adjuvant carboplatin or carboplatin and doxorubicin Vet Cancer Conf Proc 39
- Leibman NF, Kuntz CA, Steyn PF, et al. Accuracy of radiography, nuclear scintigraphy, and histopathology for determining the proximal extent of distal radius osteosarcoma in dogs. Vet Surg 2001;30:240–5.
- Wallack ST, Wisner ER, Werner JA, et al. Accuracy of magnetic resonance imaging for estimating intramedullary osteosarcoma extent in preoperative planning of canine limb-salvage procedures. Vet Radiol Ultrasound 2002;43:432–41.
- Biodegradable Cisplatin Polymer in Limb-Sparing Surgery for Canine Osteosarcoma
Annals of Surgical Oncology
Volume 11, Issue 7 , pp 705-713
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Limb-sparing surgery
- Local chemotherapy
- Local tumor recurrence
- Industry Sectors
- Author Affiliations
- 1. Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado
- 6. Animal Cancer Center, Colorado State University Veterinary Teaching Hospital, 300 West Drake Road, Fort Collins, CO, 80523
- 2. Departments of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado
- 3. Comprehensive Cancer Center, Biostatistics and Computing, Duke University Medical Center, Durham, North Carolina
- 4. Kensey Nash Corporation, Exton, Pennsylvania
- 5. National Research Council, Washington, DC